Status:
COMPLETED
Using Thoracic Ultrasound to Detect Interstitial Lung Disease in Patients With Rheumatoid Arthritis
Lead Sponsor:
Torkell Ellingsen
Conditions:
Rheumatoid Arthritis and Associated Conditions
Lung Diseases, Interstitial
Eligibility:
All Genders
18+ years
Brief Summary
Background: Pulmonary diseases are significant contributors to morbidity and mortality in patients with rheumatoid arthritis (RA). One of the most common pulmonary manifestation in RA is interstitial ...
Eligibility Criteria
Inclusion
- Patients eligible for inclusion are consenting adults (≥18 years) diagnosed with RA, with presence of at least one of the following symptoms: unexplained dyspnoea, unexplained cough, residual pneumonia or a chest X-ray indicating interstitial lung disease. All patients must fulfil the 2010 criteria for RA. A diagnosis of COPD does not exclude the patient from the study.
Exclusion
- Patients with other systemic autoimmune diseases than RA (except secondary Sjøgrens syndrome) will be excluded. Other exclusion criteria are; previous or active lung cancer, lung transplant recipients and patients with known ILD or congenital lung disease, as well as patients who have had an HRCT performed within 12 months prior to the inclusion date. Patients who are unwilling or unable to provide written informed consent will also be excluded (i.e. not eligible).
Key Trial Info
Start Date :
June 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 2 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05396469
Start Date
June 10 2022
End Date
June 2 2023
Last Update
June 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rheumatology Research Unit, Dept. of Rheumatology, OUH
Odense, Denmark, 5000